Sign in

Colorectal cancer: trials that stopped early

Trials on Colorectal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

254 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.

  1. Withdrawn

    Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer

    Reason given in the registry

    “Prospective recruitment not possible”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 Jul 2022.

    Phase
    Phase 3
    Run by
    Health Clinics Limited
    Registry record
    NCT02201381
  2. Suspended

    Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM

    Reason given in the registry

    “DSMB stopped this trial due to the difference of 3-year DFS's rate between two groups more than 5% at the interim analysis in July 2021.”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 May 2022.

    Ended
    Feb 2026
    Phase
    Phase 3
    Run by
    Zhejiang University
    Registry record
    NCT02121405
  3. Withdrawn

    Calm for Cancer Patients Receiving Chemotherapy

    Reason given in the registry

    “Study was never submitted to the IRB so never received permission to or enrolled any subjects”

    Quoted unchanged from ClinicalTrials.gov; record updated 31 Mar 2022.

    Ended
    Dec 2023
    Run by
    The University of Texas Health Science Center at San Antonio
    Registry record
    NCT04345952
  4. Withdrawn

    Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

    Reason given in the registry

    “implementation issues”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Feb 2022.

    Ended
    Feb 2024
    Phase
    Phase 2
    Run by
    Roswell Park Cancer Institute
    Registry record
    NCT04119830
  5. Withdrawn

    Neoadjuvant Therapy for Localized Rectal Adenocarcinoma

    Reason given in the registry

    “lack of resources”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Nov 2021.

    Ended
    May 2025
    Phase
    Phase 2
    Run by
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT04418895
  6. Withdrawn

    Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

    Reason given in the registry

    “No approval from ethical committee”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 Sept 2021.

    Ended
    Oct 2024
    Phase
    Phase 2
    Run by
    Shanghai Minimally Invasive Surgery Center
    Registry record
    NCT04620473
  7. Withdrawn

    Single-incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer

    Reason given in the registry

    “No research funds were raised”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Sept 2021.

    Ended
    Dec 2025
    Run by
    Ruijin Hospital
    Registry record
    NCT03633539
  8. Withdrawn

    Irreversible Electroporation of Unresectable Liver Tumors

    Reason given in the registry

    “Low accrual rate”

    Quoted unchanged from ClinicalTrials.gov; record updated 26 Mar 2021.

    Ended
    Mar 2025
    Run by
    Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery
    Registry record
    NCT04404647
  9. Withdrawn

    Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

    Reason given in the registry

    “Study withdrawn prior to enrollment due to changing standard of care landscape.”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Sept 2020.

    Ended
    Mar 2024
    Phase
    Phase 2
    Run by
    MedImmune LLC
    Registry record
    NCT04145193
  10. Withdrawn

    Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer

    Reason given in the registry

    “No funding was raised”

    Quoted unchanged from ClinicalTrials.gov; record updated 17 Feb 2020.

    Ended
    Mar 2026
    Run by
    Ruijin Hospital
    Registry record
    NCT03413930
  11. Withdrawn

    Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers

    Reason given in the registry

    “No patient enrolled during the authorized period”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Jan 2020.

    Ended
    Feb 2026
    Phase
    Phase 2
    Run by
    Institut de Cancérologie de la Loire
    Registry record
    NCT03323424
  12. Withdrawn

    Sym004 Versus TAS-102 in Patients With mCRC

    Reason given in the registry

    “Study was withdrawn due to administrative reasons”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Feb 2019.

    Ended
    Dec 2025
    Phase
    Phase 3
    Run by
    Symphogen A/S
    Registry record
    NCT03717038
  13. Withdrawn

    Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer

    Reason given in the registry

    “Negative results in a similar study”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Oct 2018.

    Ended
    Feb 2025
    Phase
    Phase 2
    Run by
    Niharika Mettu
    Registry record
    NCT03340558
  14. Withdrawn

    Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers

    Reason given in the registry

    “Change in research focus”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 May 2012.

    Run by
    Stanford University
    Registry record
    NCT01031056

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.